Brooklyn, NY, Nov. 19, 2024 (GLOBE NEWSWIRE) — Epi One, a biotechnology firm centered on most cancers detection know-how, right this moment introduced its closing webinar earlier than this funding providing closes. It is scheduled for November 26, 2024, at 4:30 PM Japanese Time. This occasion presents potential buyers a direct dialog with firm management earlier than the tip of its StartEngine marketing campaign.
The webinar will function CEO, Michael Marquardt, and Chief Scientist & Founder, Dr. Fang, presenting Epi One’s work in most cancers detection, adopted by an interactive Q&A session. “We look ahead to sharing our progress and answering questions on our most cancers detection know-how,” mentioned Marquardt. “This webinar provides potential buyers detailed insights into our strategy and our plans to advance most cancers diagnostics.”
Key matters to be lined embody:
- Technical overview of Epi One’s detection methodology
- Present market panorama and alternatives
- Improvement timeline and milestones
- Stay Q&A session with firm management
The occasion marks a major level for Epi One because it concludes its StartEngine marketing campaign, which has raised over $1.5 million from greater than 300 buyers on StartEngine after elevating greater than $3.1 million privately. buyers and stakeholders can register for this closing webinar to be taught extra earlier than the marketing campaign deadline.
Occasion Particulars:
The webinar comes at a time when early most cancers detection stays a vital want in healthcare. Annually in the USA, over 1.8 million individuals obtain a most cancers analysis, and analysis persistently reveals that early detection considerably improves therapy outcomes. Through the webinar, Marquardt will talk about how Epi One’s know-how addresses this problem by way of its focused strategy to most cancers screening.
This occasion additionally supplies a possibility for buyers to grasp Epi One’s progress since launching its StartEngine marketing campaign. The corporate will share updates on its growth timeline, latest achievements, and plans for advancing its know-how by way of scientific validation. Members will find out about particular milestones achieved and upcoming aims that align with the corporate’s dedication to enhancing most cancers detection accessibility.
This Reg CF providing is made accessible by way of StartEngine Major, LLC. This funding is speculative, illiquid, and includes a excessive diploma of danger, together with the attainable lack of your whole funding.
Michael Marquardt CEO Epi One (718) 569-8789 buyers(at)epi-one.com
Market Information and Information dropped at you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
